Genotype-Guided Dosing of Coumarin Derivatives: The European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) Trial Design

• DOI: 10.2217/pgs.09.125
• Publication Date: 2009-10-20T16:10:43Z
• Authors: Rianne MF van Schie; Mia Wadelius; Farhad Kamali; Ann K Daly; Vangelis G Manolo...; Anthonius de Boer; Rita Barallon; Talitha I Verhoef; Julia Kirchheiner; Elisabeth Haschke...; Montserrat Briz; Frits R Rosendaal; William K Redekop; Munir Pirmohamed; Anke-Hilse Maitla...
• Keywords: VKORC1; Therapeutic index; Acenocoumarol

The narrow therapeutic range and wide interpatient variability in dose requirement make anticoagulation response to coumarin derivatives unpredictable. As a result, patients require frequent monitoring avert adverse effects maintain efficacy. Polymorphisms VKORC1 CYP2C9 jointly account for about 40% of the interindividual requirements. To date, several pharmacogenetic-guided dosing algorithms derivatives, predominately warfarin, have been developed. However, potential benefit these terms their safety clinical utility has not adequately investigated randomized settings. European Pharmacogenetics Anticoagulant Therapy (EU-PACT) trial will assess, single-blinded controlled with follow-up period 3 months, genotype-guided daily practice three main used Europe. primary outcome measure is percentage time international normalized ratio. This report describes design protocol trial.